Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

# AGENCY:

National Institutes of Health, HHS.

# ACTION:

Notice.

# SUMMARY:

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

# FOR FURTHER INFORMATION CONTACT:

                        Licensing information may be obtained by communicating with Betty B. Tong, Ph.D., National Institute of Diabetes and Digestive and Kidney Diseases, Technology Advancement Office, 12A South Drive Suite 3011, Bethesda, MD 20892; telephone: 301-451-7836; email:                         *tongb@mail.nih.gov.*                         A signed Confidential Disclosure Agreement may be required to receive any unpublished information.                    

# SUPPLEMENTARY INFORMATION:

Technology description follows.

## Triazole Derivatives as P2Y14 Receptor Antagonists

The technology describes the composition of small molecule compounds that are antagonists of the P2Y14 receptor. Also provided are methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P2Y14 receptor activity in a cell. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

### Potential Commercial Applications:

Development of P2Y14 receptor antagonist for treatment of disorders, such as:
    - Inflammation
    - diabetes
    - obesity
    asthma      ( print page 76088)    
    - lipid disorder
    - metabolic syndrome

### Development Stage

    - Early stage

*Inventors:*                     Kenneth A. Jacobson (NIDDK), Anna Junker, Elisa Uliassi (NIDDK), Evgeny Kiselev (NIDDK)                

*Publications:*                     Junker A, Balasubramanian R, Ciancetta A,                     *et al.,*                     Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl derivatives as P2Y14                     receptor antagonists. J. Med. Chem., 2016, 59:6149−6168.                

*Intellectual Property:*                     HHS Reference No. E-213-2015-0, U.S. Patent No. 10,683,277, issued June 16, 2020, EP Patent Application 16774825.0, filed Sept. 23, 2016, Chinese Patent Application 201680064441.5, filed Sept. 23, 2016.                

*Licensing Contact:*                     Betty B. Tong, Ph.D.; 301-451-7836;                     *tongb@mail.nih.gov. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.*

Dated: November 19, 2020.

Bei Tong,

Senior Licensing and Patenting Manager, National Institute of Diabetes and Digestive and Kidney Diseases, Technology Advancement Office. 

[FR Doc. 2020-26169 Filed 11-25-20; 8:45 am]

BILLING CODE 4140-01-P